33.27
+0.25(+0.76%)
Currency In USD
| Previous Close | 33.02 |
| Open | 33.03 |
| Day High | 33.83 |
| Day Low | 31.64 |
| 52-Week High | 53.27 |
| 52-Week Low | 29.07 |
| Volume | 778,070 |
| Average Volume | 568,806 |
| Market Cap | 2.16B |
| PE | -11.16 |
| EPS | -2.98 |
| Moving Average 50 Days | 38.04 |
| Moving Average 200 Days | 41.5 |
| Change | 0.25 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,000.3 as of March 12, 2025 at a share price of $33.27. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $903.09 as of March 12, 2025 at a share price of $33.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
GlobeNewswire Inc.
Feb 20, 2025 12:00 PM GMT
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Jan 30, 2025 12:00 PM GMT
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological